Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Similar documents
A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Approach to the Patient with Liver Disease

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Interpreting Your Tests

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

Interpreting Liver Function Tests

Disclosure. Evaluation of Abnormal Hepatic Enzymes

Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Gastrointestinal System: Accessory Organ Disorders

-Liver function tests -

Hepatology for the Nonhepatologist

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

GI Workshop Case Studies

CHAPTER 1. Alcoholic Liver Disease

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

GI DISEASE WORKSHOP CASE STUDIES

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

LIVER FUNCTION TESTS. G M Kellerman. Hunter Area Pathology Service

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Approach to Abnormal Liver Tests

Module 1 Introduction of hepatitis

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University

Approved regimens for cirrhotic patients

Monitoring Hepatitis C

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

Stick or twist management options in hepatitis C

Biochemistry Liver Function Tests (LFTs)

EVALUATION OF ABNORMAL LIVER TESTS

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Cirrhosis of the Liver

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Alpha-1 Antitrypsin Deficiency: Liver Disease

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

Intron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests

Alpha-1 Liver Disease

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

Drug therapy in patient with hepatic impairment

Having a FibroScan. Patient & Family Guide. You do not need any special preparation before having a FibroScan.

Gastrointes*nal and Liver Pathology. Kris*ne Kra5s, M.D.

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

A Rational Evidence-based Approach to Abnormal Liver Tests

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Transmission of HCV in the United States (CDC estimate)

What are LFTs? What are LFTs? 3/20/2017. Evaluation of Abnormal Liver Chemistry Tests. Transaminases. Alkaline phosphatase.

Learning Objectives. After attending this presentation, participants will be able to:

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

B C Outlines. Child-Pugh scores

New York State HCV Provider Webinar Series

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Dhanpat Jain Yale University School of Medicine, New Haven, CT

King s College Hospital NHS Foundation Trust. Acute Liver Disease: what you really need to know.

Chronic Hepatic Disease

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

Intron A Hepatitis C. Intron A (interferon alfa-2b) Description

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

May 2015 CLINICAL REFERENCE. gastroenterology

Hepatitis C Update on New Treatments

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Liver disease in 2017: challenges and opportunities

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Diagnosis and Management of PBC

Navigating the Biliary Tract with CT & MR: An Imaging Approach to Bile Duct Obstruction

Understanding Liver Disease

JAUNDICE. Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc

World Health Organization. Western Pacific Region

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Assessment of Liver Function: Implications for HCC Treatment

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

4/26/2017. Liver Transplant and Palliative Care: Teaming up to improve care

Transcription:

R.J.Bailey MD

Hepatocytes produce Proteins Clotting factors Hormones Bile Flow

Trouble.. for the liver!

Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon Iron hemochromatosis Copper Wilson s disease Alpha-1-Antitrypsin Auto Immune Chronic Active Hepatitis Bile Duct

Hepatocellular Disease Liver cells inflamed, infected, dying Patients feel unwell Lab tests: AST and ALT elevated Bilirubin not flowing through the sick cell - jaundice possible Bile salts not produced: no itch

Hepatocellular Disease NO NO NO Bilirubin Metabolism Albumin Clotting factors Hormones Filter Gut proteins Jaundice bilirubin Ascites, edema albumin Bruise, bleed INR Male- breasts Female- menses Fluids - edema Confusion EEG testes

Liver Biochemical Tests Test Pathophysiology Disease ALT Leak from damaged liver Mild to moderate Many liver problems Extra Hepatic Liver Origin Liver AST Leak from damaged liver Severe Hepatitis: viral, toxic, autoimmune, ischemic Muscle kidney RBC s, heart Clinical Clue AST/ALT > 2 Suggests alcohol or cirrhosis-any etiology.

Test Pathophysiology Liver disease Extra Hepatic Mild/moderate Many Liver Diseases Bilirubin Decreased clearance Marked: Obstruction Hepatitis Hereditary RBC breakdown Prothrombin time Decreased synthetic capacity Acute/chronic liver failure Obstruction (Vit K corrects) Albumin Decreased synthesis Chronic liver failure Vit K deficiency malabsorption malnutrition Nephrotic syndrome, enteropathy malignancy, malnutrition, inflammation

Elevated Aminotranferase History and Physical Ultrasound Drugs Prescribed Over the counter Viral Hep B Hep C Metabolic: Ferritin Fe TIBc Copper Caeruloplasmin Alpha-1- antitrypsin Fatty Liver Alcohol Diabetes Obesity Dyslipemia Autoimmune IgG Anti-actin Anti-nuclear Anti-TTG

And now comes trouble.. for the bile ducts!

Cholestasis Liver Gall Bladder Bile Duct

Cholestasis The bile is not flowing Bile is backing up Liver cells are not sick So patients are not sick Alkaline phosphatase, GGT elevated

Trouble for the Bile Duct Liver Gall Bladder Pancreas Common Gallstones Cancer of pancreas Uncommon Sclerosing Cholangitis Cholangio carcinoma Primary Biliary Cirrhosis Bile Duct

Test Pathophysiology Liver Disease Extra Hepatic Alkaline Phosphates Mild to moderate: Many Diseases Bone Placenta Gamma Glutamyl Transpeptidase (GGT) Overproduction and leakage into serum Marked: -Cholestasis obstruction -Infiltration: Tumour Granular Alcoholic hepatitis Kidney Spleen Heart Lung Pancreas Clinical Clue GGT/AP > 2.5 suggests alcohol

Elevated Alkaline Phosphatase History and Physical and Ultrasound Obstruction or Mass Pancreas Gall Stones P.S.C. No Obstruction PBC- (AMA, IgM) Infiltrative Disease HCC (AFP)

Childs Pugh Liver Tests and Prognosis 1 2 3 Ascites None Slight Moderate + Encephalopathy None Slight Moderate + Bilirubin <20 20-30 >30 Albumin >35 28-35 <28 ProthrombinTime 1-3 4-6 >6 Score Child Pugh Class Prognosis (1 year) (2 years) 5-6 A 100% 85% >9 B 81% 57% 10-15 C 45% 35% Operator dependent, 3 categories only, difficult to decide on severity

Liver Tests and Prognosis - MELD Model End Stage Liver Disease Formula: 3.8 x log (e) (bilirubin mg/dl) + 11.2 x log (e) (INR) + 9.6 log (e) (creatinine mg/dl) Consistent, Reproducable, Non-Operator Dependent or use your I-PHONE app!!

Liver Tests and Prognosis - MELD

SOMETIMES IT S NOT THAT EASY!

Cirrhosis New Ideas about Cirrhosis 1. Labs can fool you 2. Fibroscan Very Helpful 3. Concept changes

Cirrhosis Child s & MELD are static pictures and may over or under diagnose cirrhosis -based on sampling errors at biopsy Cirrhosis may be clinically unnoticeable (compensated) or decompensated Compensated cirrhosis may have varying levels of portal hypertension (HVPG) Am J. Gastroenterol 2002, Hepatology 2006

How can we document in cirrhosis (easily) FibroScan measures the liver stiffness and quantify the hepatic fibrosis in a non-invasive and painless way.

Explored volume Probe positioning and measurement point 25 to 65 mm 3 cm 3 Explored volume is 3 cm 3 with M probe examination

Examples in human liver V S = 1.1 m/s E ~ 3 kpa V S = 1.7 m/s E ~ 9 kpa V S = 3.6 m/s E ~ 40 kpa E V S 2

Correlation between LSM and Fibrosis stages

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis Histological F1-F3 F4 Clinical Non-cirrhotic Compensated Compensated Decompensated Decompensated Symptoms None None (no varices) None (varices present) Ascites, VH, Encephalopathy Infection Renal Failure Sub-Stage Stage 1 Stage 2 Stages 3 and 4 Stages 5 and 6 Hemodynamic (HVPG, mmhg) >6 >10 >12 Biological Fibrogenesis and Angiogenesis Scar and X-linking Thick (acellular) scar and nodules Insoluble scar Insoluble scar ORIGINAL ALTERED BY R.J.BAILEY HepatologyVOL 51;pages 1445-1449HEPATOLOGY 2010; 51: 2069-2076. Am J Gastroenterol 2010; 105: 2164-2172.

Clinical Stage 1 Compensated Cirrhosis Mortality 1% per year

Clinical Stage 2 Compensated Cirrhosis with Varices Mortality 3-4% per year

Ascites Mortality 20% per year

GI Bleeding Mortality 57% per year

Infection/Renal Failure Mortality 67% per year

SOMETIMES IT S NOT THAT EASY!

What Do You Think? Male 47 years Alcohol 3 bottles of a beer a day Past Seizures- (dilantin controlled) 5 10-210 lbs Ultrasound- Normal Labs Bilirubin(20) 40 AST (50) 57 ALT (40) 42 Alk Phos (130) 130 GGT (70) 487 Alcoholic Hepatitis Drug Induced Metabolic Syndrome Gilbert s Cirrhosis

Male 47 Years 5 10 190 lbs Physical Exam Normal Ultrasound- non homogenous Labs Bilirubin 22 ALT (40) 62 AST (50) 62 Alk Phos (130) 137 GGT (70) 102 Ferritin (30-300) 962 Hep C Ab Pos Hemochromatosis or Hepatitis C

Ferritin Elevation Intracellular Iron Storage (hemochromatosis) Acute Phase Response Hemochromatosis? or Hepatitis C? Genetics Hepatitis C RNA

Hepatitis C Hep C Ab 75% Hepatitis C 25 % Hepatitis C Cleared Genotypes 1-6 Influences therapy IL-28 CC CT TT RX Coming Pegylated Interferon Ribavirin Boceprevir or Telaprevir Sofosbuvir Semiprevir

Hepatitis B Hep B S Ag Hep BV DNA Hep B e Ag Hep B e Ab ALT Fibroscan Rx for life positive 20,000 IU 2,000 IU 20,000 IU 2,000 IU 30 for men 20 for women F1 F2 F3 F4 Entecavir Tenofovir

Liver: Abnormal Enzymes: Thank you R.J.Bailey MD